Paradigm, a molecular information & Next Generation Sequencing corporation specializing in providing testing for cancer patients recently announced that it has entered into a contractual agreement with UnitedHealthcare for coverage of PCDx™.
PCDx™ is a Next-Generation Sequencing (NGS) based diagnostic test that is designed to provide physicians and patients with a more targeted, personalized approach to cancer treatment by identifying the underlying genomic and proteomic alterations of a patient’s tumor’s DNA, RNA & Protein.